AR130179A1 - Terapias combinadas para el tratamiento de la cirrosis con hipertensión portal - Google Patents
Terapias combinadas para el tratamiento de la cirrosis con hipertensión portalInfo
- Publication number
- AR130179A1 AR130179A1 ARP230102120A ARP230102120A AR130179A1 AR 130179 A1 AR130179 A1 AR 130179A1 AR P230102120 A ARP230102120 A AR P230102120A AR P230102120 A ARP230102120 A AR P230102120A AR 130179 A1 AR130179 A1 AR 130179A1
- Authority
- AR
- Argentina
- Prior art keywords
- cirrhosis
- treatment
- subject
- portal hypertension
- combined therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Un método para tratar la cirrosis hepática en un sujeto que lo necesite. El método incluye administrar al sujeto una composición. La composición incluye una cantidad terapéuticamente eficaz de zibotentan y dapagliflozin. Reivindicación 1: Un método para tratar la cirrosis hepática en un sujeto que lo necesite, que comprende administrar al sujeto una composición que comprende una cantidad terapéuticamente eficaz de zibotentan y dapagliflozina. Reivindicación 62: Una forma farmacéutica oral, que comprende: a. de aproximadamente 0.25 mg a aproximadamente 20 mg de zibotentan; b. de aproximadamente 0.5 mg a aproximadamente 40 mg de dapagliflozina; y c. un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263371228P | 2022-08-12 | 2022-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130179A1 true AR130179A1 (es) | 2024-11-13 |
Family
ID=87760695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102120A AR130179A1 (es) | 2022-08-12 | 2023-08-11 | Terapias combinadas para el tratamiento de la cirrosis con hipertensión portal |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240058331A1 (es) |
| EP (1) | EP4568673A1 (es) |
| JP (1) | JP2025526746A (es) |
| KR (1) | KR20250044929A (es) |
| CN (1) | CN119855594A (es) |
| AR (1) | AR130179A1 (es) |
| AU (1) | AU2023321653A1 (es) |
| CA (1) | CA3264757A1 (es) |
| CL (1) | CL2025000385A1 (es) |
| IL (1) | IL318945A (es) |
| MX (1) | MX2025001713A (es) |
| TW (1) | TW202423417A (es) |
| UY (1) | UY40392A (es) |
| WO (1) | WO2024033519A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| US20220257626A1 (en) * | 2019-07-23 | 2022-08-18 | Novartis Ag | Treatment comprising sglt inhibitors |
| IL299568A (en) * | 2020-07-10 | 2023-02-01 | Astrazeneca Ab | A combination of zibutantan and dapagliflozin for the treatment of chronic kidney disease |
-
2023
- 2023-08-11 AR ARP230102120A patent/AR130179A1/es unknown
- 2023-08-11 WO PCT/EP2023/072278 patent/WO2024033519A1/en not_active Ceased
- 2023-08-11 JP JP2025507522A patent/JP2025526746A/ja active Pending
- 2023-08-11 US US18/448,559 patent/US20240058331A1/en active Pending
- 2023-08-11 AU AU2023321653A patent/AU2023321653A1/en active Pending
- 2023-08-11 KR KR1020257008116A patent/KR20250044929A/ko active Pending
- 2023-08-11 EP EP23757862.0A patent/EP4568673A1/en active Pending
- 2023-08-11 CN CN202380059072.0A patent/CN119855594A/zh active Pending
- 2023-08-11 IL IL318945A patent/IL318945A/en unknown
- 2023-08-11 CA CA3264757A patent/CA3264757A1/en active Pending
- 2023-08-11 TW TW112130316A patent/TW202423417A/zh unknown
- 2023-08-14 UY UY0001040392A patent/UY40392A/es not_active Application Discontinuation
-
2025
- 2025-02-10 CL CL2025000385A patent/CL2025000385A1/es unknown
- 2025-02-11 MX MX2025001713A patent/MX2025001713A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058331A1 (en) | 2024-02-22 |
| TW202423417A (zh) | 2024-06-16 |
| WO2024033519A1 (en) | 2024-02-15 |
| KR20250044929A (ko) | 2025-04-01 |
| MX2025001713A (es) | 2025-04-02 |
| CN119855594A (zh) | 2025-04-18 |
| IL318945A (en) | 2025-04-01 |
| AU2023321653A1 (en) | 2025-03-27 |
| JP2025526746A (ja) | 2025-08-15 |
| CL2025000385A1 (es) | 2025-07-04 |
| CA3264757A1 (en) | 2024-02-15 |
| UY40392A (es) | 2024-02-15 |
| EP4568673A1 (en) | 2025-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| CO5640076A2 (es) | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento | |
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| FI3638696T3 (fi) | Anti-cd70 vasta-aineen argx-110 käyttö akuutin myeloidileukemian hoitoon | |
| ES2144119T3 (es) | Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada. | |
| AR063109A1 (es) | Terapias topicas para la mucositis oral y otras afecciones | |
| AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
| JP2002523370A5 (es) | ||
| MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| MX2023005078A (es) | Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. | |
| AR074603A1 (es) | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| EA200200995A1 (ru) | Применение композиций азалидных антибиотиков для лечения или предупреждения бактериальных или протозойных инфекций у млекопитающих | |
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| IL320562A (en) | Cancer treatment methods | |
| AR130179A1 (es) | Terapias combinadas para el tratamiento de la cirrosis con hipertensión portal | |
| CL2004000765A1 (es) | Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo. | |
| GB2591937A (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| MX2025000740A (es) | Compuestos estrogenicos er-beta y metodos de uso | |
| CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a |